Consumer lobbyists are skeptical of HHS’ $354 million award to Virginia start-up Phlow Corp. to make generic drugs for hospitals because one of the company’s founders was an executive at a company that quintupled the price of naloxone during the opioid epidemic. HHS’ Biomedical Advanced Research and Development Authority granted the award, which can be extended to $812 million. Phlow will use the money to produce drugs that treat hospitalized patients for COVID-19-related illnesses. The company also will stockpile ingredients...